Optimizing Precision Neurology Trials Through Biomarkers and Real-World Data

The upcoming session targets the intersection of patient identification and precision medicine, focusing on how sponsors can better navigate the lifecycle of drug development. By leveraging biomarkers and real-world evidence, researchers aim to refine their understanding of disease progression and improve decision-making from early-stage trials through post-launch planning.

Speakers including Zhe Rachel Angerer of PPD Clinical Research Services, Tracy Jerome Stalvey, Ariel Berger, and Clario’s David Scott will provide tactical guidance on optimizing trial efficiency. The discussion will center on practical applications of digital solutions and evidence-based planning to help sponsors identify appropriate patient populations and achieve market access goals more effectively. The live broadcast is scheduled for 10am EDT on July 15, 2026.